.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Chubb
Covington
Julphar
Fuji
QuintilesIMS
Queensland Health
Mallinckrodt
Harvard Business School
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Patent: 07114459

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-002Jan 30, 2015RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimJARDIANCEempagliflozinTABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimJARDIANCEempagliflozinTABLET;ORAL204629-002Aug 1, 2014RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist